Press Releases

Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Lipella has enrolled and treated the first patient in a 36-subject, Phase-2a, U.S. clinical trial de...

27 August 2015

Lipella Pharmaceuticals to Present at the BIO International Convention

Lipella Pharmaceuticals will present at the 2015 Bio International Meeting in Philadelphia, PA on Tu...

12 June 2015

Lipella Pharmaceuticals to Present at the AUA 2015 Annual Meeting

Lipella Pharmaceuticals’ LP‐10 asset, which has received FDA Orphan Drug designation, has now...

16 May 2015

Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder

PITTSBURGH--(BUSINESS WIRE)--A physician-initiated, double-blind, randomized, placebo-controlled cli...

08 April 2015

Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial

PITTSBURGH--(BUSINESS WIRE)--Pittsburgh based Lipella Pharmaceuticals Inc. today announced newly pub...

08 December 2014

Lipella Pharmaceuticals Receives National Institutes of Health Funding for Its Orphan Drug Program

PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., today announced the award of a grant by t...

13 May 2014

Lipella Pharmaceuticals Inc. Names David Lucchino to Board of Directors

Lipella Pharmaceuticals Inc. today announced the appointment of David L. Lucchino, co-founder and fo...

03 September 2013